Collectively, microglial PKCδ in hypothalamus holds promise as a potential therapeutic target for enhancing lipid metabolism, particularly in fatty liver diseases, which differs significantly from current concepts of lipid metabolism regulation. This evidence concerns the gene PRKCD and fatty liver disease.